Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

Helminth-Based Product and the Microbiome of Mice with Lupus.

Neuman H, Mor H, Bashi T, Givol O, Watad A, Shemer A, Volkov A, Barshack I, Fridkin M, Blank M, Shoenfeld Y, Koren O.

mSystems. 2019 Feb 19;4(1). pii: e00160-18. doi: 10.1128/mSystems.00160-18. eCollection 2019 Jan-Feb.

2.

The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis.

Croci S, Bonacini M, Muratore F, Caruso A, Fontana A, Boiardi L, Soriano A, Cavazza A, Cimino L, Belloni L, Perry O, Fridkin M, Parmeggiani M, Blank M, Shoenfeld Y, Salvarani C.

J Autoimmun. 2019 Mar;98:113-121. doi: 10.1016/j.jaut.2019.01.002. Epub 2019 Jan 10.

PMID:
30638709
3.

Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis.

Blank M, Bashi T, Lachnish J, Ben-Ami-Shor D, Shovman O, Fridkin M, Eisenstein M, Volkov A, Barshack I, Shoenfeld Y.

PLoS One. 2018 Aug 8;13(8):e0200615. doi: 10.1371/journal.pone.0200615. eCollection 2018.

4.

Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model.

Shemer A, Kivity S, Shovman O, Bashi T, Perry O, Watad A, Ben-Ami Shor D, Volkov A, Barshack I, Bragazzi NL, Krule A, Fridkin M, Amital H, Blank M, Shoenfeld Y.

Clin Exp Immunol. 2018 Aug;193(2):160-166. doi: 10.1111/cei.13137.

5.

Tuftsin-Phosphorylcholine Maintains Normal Gut Microbiota in Collagen Induced Arthritic Mice.

Ben-Amram H, Bashi T, Werbner N, Neuman H, Fridkin M, Blank M, Shoenfeld Y, Koren O.

Front Microbiol. 2017 Jul 10;8:1222. doi: 10.3389/fmicb.2017.01222. eCollection 2017.

6.
7.

Novel therapeutic compound tuftsin-phosphorylcholine attenuates collagen-induced arthritis.

Bashi T, Shovman O, Fridkin M, Volkov A, Barshack I, Blank M, Shoenfeld Y.

Clin Exp Immunol. 2016 Apr;184(1):19-28. doi: 10.1111/cei.12745. Epub 2016 Feb 4.

8.

Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine.

Bashi T, Blank M, Ben-Ami Shor D, Fridkin M, Versini M, Gendelman O, Volkov A, Barshak I, Shoenfeld Y.

J Autoimmun. 2015 May;59:1-7. doi: 10.1016/j.jaut.2015.03.001. Epub 2015 Apr 10.

PMID:
25864802
9.

New approaches to treating Alzheimer's disease.

Zheng H, Fridkin M, Youdim M.

Perspect Medicin Chem. 2015 Feb 9;7:1-8. doi: 10.4137/PMC.S13210. eCollection 2015.

10.

Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors.

Cooper I, Last D, Guez D, Sharabi S, Elhaik Goldman S, Lubitz I, Daniels D, Salomon S, Tamar G, Tamir T, Mardor R, Fridkin M, Shechter Y, Mardor Y.

J Cereb Blood Flow Metab. 2015 Jun;35(6):967-76. doi: 10.1038/jcbfm.2015.6. Epub 2015 Feb 11.

11.

Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease.

Ben-Ami Shor D, Bashi T, Lachnish J, Fridkin M, Bizzaro G, Barshak I, Blank M, Shoenfeld Y.

J Autoimmun. 2015 Jan;56:111-7. doi: 10.1016/j.jaut.2014.11.001. Epub 2014 Dec 3.

PMID:
25479760
12.

From single target to multitarget/network therapeutics in Alzheimer's therapy.

Zheng H, Fridkin M, Youdim M.

Pharmaceuticals (Basel). 2014 Jan 23;7(2):113-35. doi: 10.3390/ph7020113.

13.

Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model.

Marcus Y, Shefer G, Sasson K, Kohen F, Limor R, Pappo O, Nevo N, Biton I, Bach M, Berkutzki T, Fridkin M, Benayahu D, Shechter Y, Stern N.

Diabetes. 2013 Apr;62(4):1121-30. doi: 10.2337/db12-0792. Epub 2012 Dec 18.

14.

Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins.

Cooper I, Sasson K, Teichberg VI, Schnaider-Beeri M, Fridkin M, Shechter Y.

J Biol Chem. 2012 Dec 28;287(53):44676-83. doi: 10.1074/jbc.M112.395384. Epub 2012 Nov 13.

15.

Establishing the principle of reversibility in peptide/protein and small-molecule therapy.

Shechter Y, Sasson K, Marcus Y, Rubinraut S, Lev-Goldman V, Fridkin M.

Ther Deliv. 2012 Jan;3(1):17-23. Review.

PMID:
22833930
16.

Newly designed modifier prolongs the action of short-lived peptides and proteins by allowing their binding to serum albumin.

Shechter Y, Sasson K, Lev-Goldman V, Rubinraut S, Rubinstein M, Fridkin M.

Bioconjug Chem. 2012 Aug 15;23(8):1577-86. doi: 10.1021/bc3000854. Epub 2012 Jul 17.

PMID:
22759320
17.

Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy.

Zheng H, Fridkin M, Youdim MB.

Curr Drug Targets. 2012 Jul;13(8):1089-106. Review.

PMID:
22676912
18.

From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.

Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA.

J Alzheimers Dis. 2012;30(1):1-16. doi: 10.3233/JAD-2012-120013. Review.

PMID:
22387411
20.

β2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3β expression and reduces experimental-antiphospholipid-syndrome.

Blank M, Baraam L, Eisenstein M, Fridkin M, Dardik R, Heldman Y, Katchalski-Katzir E, Shoenfeld Y.

J Autoimmun. 2011 Aug;37(1):8-17. doi: 10.1016/j.jaut.2011.02.008. Epub 2011 Apr 27.

PMID:
21524885
21.

Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

Zheng H, Youdim MB, Fridkin M.

ACS Chem Neurosci. 2010 Nov 17;1(11):737-46. doi: 10.1021/cn100069c. Epub 2010 Oct 4.

22.

Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

Zheng H, Fridkin M, Youdim MB.

Neurochem Res. 2010 Dec;35(12):2117-23. doi: 10.1007/s11064-010-0293-1. Epub 2010 Oct 28.

PMID:
20981484
23.

Delivery of neuropeptides from the periphery to the brain: studies with enkephalin.

Shechter Y, Heldman E, Sasson K, Bachar T, Popov M, Fridkin M.

ACS Chem Neurosci. 2010 May 19;1(5):399-406. doi: 10.1021/cn100001j. Epub 2010 Feb 16.

24.

Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.

Zheng H, Youdim MB, Fridkin M.

ACS Chem Biol. 2010 Jun 18;5(6):603-10. doi: 10.1021/cb900264w.

PMID:
20455574
25.

Relation between serum amyloid A truncated peptides and their suprastructure chirality.

Rubin N, Perugia E, Wolf SG, Klein E, Fridkin M, Addadi L.

J Am Chem Soc. 2010 Mar 31;132(12):4242-8. doi: 10.1021/ja909345p.

PMID:
20218685
26.

Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.

Sasson K, Marcus Y, Lev-Goldman V, Rubinraut S, Fridkin M, Shechter Y.

J Control Release. 2010 Mar 3;142(2):214-20. doi: 10.1016/j.jconrel.2009.10.028. Epub 2009 Oct 30.

PMID:
19883707
27.

Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Gal S, Zheng H, Fridkin M, Youdim MB.

Neurotox Res. 2010 Jan;17(1):15-27. doi: 10.1007/s12640-009-9070-9. Epub 2009 Jul 16.

PMID:
19609632
28.

Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.

Zheng H, Youdim MB, Fridkin M.

J Med Chem. 2009 Jul 23;52(14):4095-8. doi: 10.1021/jm900504c.

PMID:
19485411
29.

Restrain of bone growth by estrogen-mimetic peptide-1 (EMP-1): a micro-computed tomographic study.

Kasher R, Bajayo A, Gabet Y, Nevo N, Fridkin M, Katchalski-Katzir E, Kohen F, Bab I.

Peptides. 2009 Jun;30(6):1181-6. doi: 10.1016/j.peptides.2009.02.019. Epub 2009 Mar 14.

PMID:
19463753
30.

The amyloidogenic domains of the human serum amyloid A protein--new insights.

Perugia E, Monticelli E, Rubinraut S, Kapitkovsky A, Fridkin M.

Adv Exp Med Biol. 2009;611:69-70. No abstract available.

PMID:
19400097
31.

Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin.

Marcus Y, Sasson K, Fridkin M, Shechter Y.

J Med Chem. 2008 Jul 24;51(14):4300-5. doi: 10.1021/jm8002558. Epub 2008 Jun 25.

PMID:
18578475
32.

Conjugates of gonadotropin releasing hormone (GnRH) with carminic acid: Synthesis, generation of reactive oxygen species (ROS) and biological evaluation.

Lev-Goldman V, Mester B, Ben-Aroya N, Hanoch T, Rupp B, Stanoeva T, Gescheidt G, Seger R, Koch Y, Weiner L, Fridkin M.

Bioorg Med Chem. 2008 Jul 15;16(14):6789-98. doi: 10.1016/j.bmc.2008.05.057. Epub 2008 Jun 19.

PMID:
18571926
33.

Reversible pegylation of insulin facilitates its prolonged action in vivo.

Shechter Y, Mironchik M, Rubinraut S, Tsubery H, Sasson K, Marcus Y, Fridkin M.

Eur J Pharm Biopharm. 2008 Sep;70(1):19-28. doi: 10.1016/j.ejpb.2008.03.018. Epub 2008 Apr 7.

PMID:
18495444
34.

The molecular and cellular basis of exostosis formation in hereditary multiple exostoses.

Trebicz-Geffen M, Robinson D, Evron Z, Glaser T, Fridkin M, Kollander Y, Vlodavsky I, Ilan N, Law KF, Cheah KS, Chan D, Werner H, Nevo Z.

Int J Exp Pathol. 2008 Oct;89(5):321-31. doi: 10.1111/j.1365-2613.2008.00589.x. Epub 2008 Apr 30.

35.

Chirality of amyloid suprastructures.

Rubin N, Perugia E, Goldschmidt M, Fridkin M, Addadi L.

J Am Chem Soc. 2008 Apr 9;130(14):4602-3. doi: 10.1021/ja800328y. Epub 2008 Mar 14.

PMID:
18338897
36.

Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive.

Cohen N, Stolarsky-Bennun M, Amir-Kroll H, Margalit R, Nussbaum G, Cohen-Sfady M, Pevsner-Fischer M, Fridkin M, Bercovier H, Eisenbach L, Jung S, Cohen IR.

J Immunol. 2008 Feb 15;180(4):2409-18.

37.

Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties.

Van der Schyf CJ, Mandel S, Geldenhuys WJ, Amit T, Avramovich Y, Zheng H, Fridkin M, Gal S, Weinreb O, Bar Am O, Sagi Y, Youdim MB.

Curr Alzheimer Res. 2007 Dec;4(5):522-36. Review.

PMID:
18220515
38.

A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.

Blat D, Weiner L, Youdim MB, Fridkin M.

J Med Chem. 2008 Jan 10;51(1):126-34. Epub 2007 Dec 14.

PMID:
18078312
39.

'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.

Tirosh B, Daniel-Carmi V, Carmon L, Paz A, Lugassy G, Vadai E, Machlenkin A, Bar-Haim E, Do MS, Ahn IS, Fridkin M, Tzehoval E, Eisenbach L.

Br J Cancer. 2007 Dec 17;97(12):1655-63. Epub 2007 Dec 11.

40.

Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide.

Nesher M, Vachutinsky Y, Fridkin G, Schwarz Y, Sasson K, Fridkin M, Shechter Y, Lichtstein D.

Bioconjug Chem. 2008 Jan;19(1):342-8. Epub 2007 Dec 11.

PMID:
18069777
41.

Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.

Dangoor D, Biondi B, Gobbo M, Vachutinski Y, Fridkin M, Gozes I, Rocchi R.

J Pept Sci. 2008 Mar;14(3):321-8.

PMID:
17924396
42.

Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG.

Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, Youdim MB.

Curr Alzheimer Res. 2007 Sep;4(4):403-11.

PMID:
17908043
43.

Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.

Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, Le W.

FASEB J. 2007 Dec;21(14):3835-44. Epub 2007 Aug 9.

PMID:
17690154
44.

The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model.

Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, Cervera R, Font J, Fridkin M, Thiesen HJ, Shoenfeld Y.

Int Immunol. 2007 Jul;19(7):857-65. Epub 2007 Jun 18.

PMID:
17576752
45.

Novel analogs of VIP with multiple C-terminal domains.

Dangoor D, Rubinraut S, Fridkin M, Gozes I.

Peptides. 2007 Sep;28(9):1622-30. Epub 2007 Mar 30.

PMID:
17481779
47.

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.

Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB.

J Neurochem. 2007 Jan;100(2):490-502. Epub 2006 Nov 27.

48.

[Luliberin analogues exhibiting a cytotoxic effect on tumor cells in vitro].

Burov SV, Iablokova TV, Dorosh MIu, Shkarubskaia ZP, Blank M, Epshteĭn N, Fridkin M.

Bioorg Khim. 2006 Sep-Oct;32(5):459-66. Russian.

PMID:
17042263
49.
50.

Novel extended and branched N-terminal analogs of VIP.

Dangoor D, Rubinraut S, Fridkin M, Gozes I.

Regul Pept. 2006 Nov 15;137(1-2):42-9. Epub 2006 Sep 8.

PMID:
16962672

Supplemental Content

Loading ...
Support Center